A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Conditions
Advanced Urothelial Carcinoma · Oral Drug Administration · Open Label
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Contact: Principal Investigator (Terry Friedlander, MD)Yale Cancer Center, New Haven, Connecticut, United States
Contact: Principal Investigator (Daniel Petrylak, MD)Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, United States
Contact: Principal Investigator (Jaime R Merchan, MD MMSc)The University of Chicago Medicine, Chicago, Illinois, United States
Contact: Principal Investigator (Randy Sweis, MD)Mass General Cancer Center, Boston, Massachusetts, United States
Contact: Principal Investigator (Xin Gao, MD)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Joaquim Bellmunt, MD, Ph.D.)Icahn School of Medicine at Mount Sinai, New York, New York, United States
Contact: Principal Investigator (Matthew Galsky, MD)Memorial Slone Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Gopa Iyer, MD)UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Contact: Principal Investigator (Matthew Milowsky, MD)The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Contact: Principal Investigator (Shilpa Gupta, MD)Sarah Cannon Research Institute, Nashville, Tennessee, United States
Contact: Principal Investigator (Benjamin Garmezy, MD)Houston Methodist Cockrell Center for Advanced Therapeutics, Houston, Texas, United States
Contact: Principal Investigator (Patrick Prath, MD)
Study leads
Gopa Iyer, MD
Principal Investigator
Memorial Slone Kettering